Zijun Y Xu-Monette, Qipan Deng, Ganiraju C Manyam, Alexander Tzankov, Ling Li, Yi Xia, Xiao-Xiao Wang, Dehui Zou, Carlo Visco, Karen Dybkær, Jun Li, Li Zhang, Han Liang, Santiago Montes-Moreno, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L Richards, Eric D Hsi, William W L Choi, J Han van Krieken, Jooryung Huh, Maurilio Ponzoni, Andrés J M Ferreri, Ben M Parsons, Michael B Møller, Sa A Wang, Roberto N Miranda, Miguel A Piris, Jane N Winter, L Jeffrey Medeiros, Yong Li, Ken H Young
PURPOSE: MYC is a critical driver oncogene in many cancers, and its deregulation in the forms of translocation and overexpression has been implicated in lymphomagenesis and progression of diffuse large B-cell lymphoma (DLBCL). The MYC mutational profile and its roles in DLBCL are unknown. This study aims to determine the spectrum of MYC mutations in a large group of patients with DLBCL, and to evaluate the clinical significance of MYC mutations in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) immunochemotherapy...
July 15, 2016: Clinical Cancer Research